{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:07:17Z","timestamp":1782918437248,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.euroneuro.2015.04.027","type":"journal-article","created":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T01:19:36Z","timestamp":1430961576000},"page":"1669-1676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study"],"prefix":"10.1016","volume":"25","author":[{"given":"Benjamin","family":"Sneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie Gry","family":"Pristed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9868-7028","authenticated-orcid":false,"given":"Jimmi","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2015.04.027_bib1","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/acps.12144","article-title":"Involuntary treatment of schizophrenia patients 2004\u20132010 in Denmark","volume":"129","author":"Andersen","year":"2014","journal-title":"Acta Psychiatrica Scand."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophrenia Bull."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0447.2005.00589.x","article-title":"Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy","volume":"113","author":"Carnahan","year":"2006","journal-title":"Acta Psychiatrica Scand."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.47102\/annals-acadmedsg.V35N7p457","article-title":"Reducing polypharmacy through the introduction of a treatment algorithm: use of a treatment algorithm on the impact on polypharmacy","volume":"35","author":"Chong","year":"2006","journal-title":"Ann. Acad. Med. Singapore"},{"key":"10.1016\/j.euroneuro.2015.04.027_bib6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1176\/appi.ps.51.2.250","article-title":"Effect of clozapine on polypharmacy","volume":"51","author":"Chong","year":"2000","journal-title":"Psychiatric Serv."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2006.08.017","article-title":"Does antipsychotic polypharmacy increase the risk for metabolic syndrome?","volume":"89","author":"Correll","year":"2007","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.psc.2012.06.007","article-title":"Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice","volume":"35","author":"Correll","year":"2012","journal-title":"Psychiatric Clin. North Am."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophrenia Bull."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.schres.2011.02.016","article-title":"Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior","volume":"131","author":"Correll","year":"2011","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/appi.ajp.2011.10060908","article-title":"Effectiveness of switching from antipsychotic polypharmacy to monotherapy","volume":"168","author":"Essock","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.04.027_bib12","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial","volume":"13","author":"Fleischhacker","year":"2010","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2015.04.027_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14740338.2012.683523","article-title":"Safety and tolerability of antipsychotic polypharmacy","volume":"11","author":"Gallego","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects","volume":"14","author":"Hasan","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.04.027_bib16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1440-1819.2011.02280.x","article-title":"Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia","volume":"65","author":"Hazra","year":"2011","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0447.2005.00612.x","article-title":"An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia","volume":"113","author":"Henderson","year":"2006","journal-title":"Acta Psychiatrica Scand."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib18","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.jpsychires.2013.08.024","article-title":"Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients","volume":"47","author":"Hori","year":"2013","journal-title":"J. Psychiatric Res."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib19","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/j.1440-1614.2004.01340.x","article-title":"An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand","volume":"38","author":"Humberstone","year":"2004","journal-title":"Aust. N.Z. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.04.027_bib20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.9758\/cpn.2014.12.2.128","article-title":"Prescription patterns for patients with schizophrenia in Korea: a focus on antipsychotic polypharmacy","volume":"12","author":"Kim","year":"2014","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-244X-11-118","article-title":"Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects? A cross-sectional study","volume":"11","author":"Misawa","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.04.027_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.schres.2010.12.011","article-title":"Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study","volume":"127","author":"Muscatello","year":"2011","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib23","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0269881108100320","article-title":"Psychiatrists\u2019 attitude towards and knowledge of clozapine treatment","volume":"24","author":"Nielsen","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/JCP.0b013e318248dfb8","article-title":"Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study","volume":"32","author":"Nielsen","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1600-0447.2010.01576.x","article-title":"10-year trends in the treatment and outcomes of patients with first-episode schizophrenia","volume":"122","author":"Nielsen","year":"2010","journal-title":"Acta Psychiatrica Scand."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/schbul\/sbq137","article-title":"Risk factors for ileus in patients with schizophrenia","volume":"38","author":"Nielsen","year":"2012","journal-title":"Schizophrenia Bull."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib27","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/JCP.0b013e318267b3cd","article-title":"Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study","volume":"32","author":"Nielsen","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.euroneuro.2012.03.003","article-title":"Geographical and temporal variations in clozapine prescription for schizophrenia","volume":"22","author":"Nielsen","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/YIC.0b013e328303ac75","article-title":"Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages?","volume":"23","author":"Nose","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00131746-200507000-00005","article-title":"Antipsychotic polypharmacy: is there evidence for its use?","volume":"11","author":"Patrick","year":"2005","journal-title":"J. Psychiatric Pract."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib32","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1176\/appi.ajp.161.7.1308","article-title":"Worsening schizoaffective disorder with aripiprazole","volume":"161","author":"Reeves","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.04.027_bib33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1192\/bjp.171.6.569","article-title":"Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study","volume":"171","author":"Shiloh","year":"1997","journal-title":"Br. J. Psychiatry J. Mental Science"},{"key":"10.1016\/j.euroneuro.2015.04.027_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.schres.2012.10.015","article-title":"Interventions to reduce antipsychotic polypharmacy: a systematic review","volume":"143","author":"Tani","year":"2013","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.2011.01792.x","article-title":"Augmentation of clozapine with a second antipsychotic\u2014a meta-analysis","volume":"125","author":"Taylor","year":"2012","journal-title":"Acta Psychiatrica Scand."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2407-8-31","article-title":"The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study","volume":"8","author":"Tetsche","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euroneuro.2015.04.027_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.schres.2011.03.001","article-title":"Characteristics and predictors of long-term institutionalization in patients with schizophrenia","volume":"131","author":"Uggerby","year":"2011","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib38","first-page":"A4578","article-title":"The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good","volume":"60","author":"Uggerby","year":"2013","journal-title":"Danish Med. J."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib39","article-title":"Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations","author":"Velligan","year":"2014","journal-title":"Psychiatric Serv."},{"key":"10.1016\/j.euroneuro.2015.04.027_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/YCO.0b013e3283366427","article-title":"Polypharmacy in schizophrenia","volume":"23","author":"Zink","year":"2010","journal-title":"Curr. Opin. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15001479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15001479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T04:38:39Z","timestamp":1691642319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X15001479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0924977X15001479"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.04.027","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}